PTC
PDLI

Private Trust Company’s PDL BioPharma, Inc. PDLI Stock Holding History

Private Trust Company’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,350
Closed -$11K – 1868
2013
Q3 		$11K Hold
1,350
– – 0.01% 899
2013
Q2 		$10K Buy
+1,350
New +$10.5K ﹤0.01% 873

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Gotham Asset Management
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Private Trust Company's PDLI Position: Q4 2013 in Review

Private Trust Company sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 1,350 shares — an estimated $11K sold.

Private Trust Company first reported a position in PDLI in Q2 2013 and held it in 2 quarters. The position peaked at $11K in Q3 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

  • Private Trust Company reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Private Trust Company sold 1,350 PDL BioPharma, Inc. shares in Q4 2013, an estimated $11K.
  • Private Trust Company first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 2 quarters.
  • Private Trust Company's PDL BioPharma, Inc. position peaked at $11K in Q3 2013.
  • 224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Private Trust Company's 13F filing for Q4 2013, filed 8 Jan 2014.